Several studies have demonstrated that low-dose PI3K-AKT inhibitors are effective in reversing paclitaxel resistance in different tumor types, including gastric, ovarian, lung, and prostate cancers (36–39). This evidence concerns the gene AKT1 and prostate cancer.